Generex Biotechnology Investing DD 2020 In the I-Box
1)
Generex Biotechnology Investing DD 2020 In the I-Box
1) The CEO Joe Moscato is a marketing guy and he knows how to get everyone to see the big picture and to take long term views. Even if it means taking less pay now for rewards later. Including himself. No big fat salary for Joe now. In fact he has pretty much deferred any salary. What CEO does that?
2) GNBT filed an S-1 registration with the SEC with the future plans all noted. When the S-1 gets approved they have financing approved for a minimum of $40M to be used if needed. Think of it as a line of credit. The S-1 could be approved ANY day.
3) The financing allows them to purchase a majority interest privately held company named Altucell who may have a treatment which may cure Type 1 Diabetes. This companies research is fairly advanced and additional trials are about ready to go once funding arrives. Why?
from Generex:
"as part of our due diligence
process, we pinpointed specific, comparable deals that validate the huge value of the
ALTuCELL acquisition, as evidenced by the recently announced purchase of Semma
Therapeutics by Vertex Pharmaceuticals for close to a billion dollars."
4) Generex is spinning off NGIO and it should be trading on the Nazdaq within a few weeks. It will be owned by Generex shareholders as we have been awarded dividend shares and ~70% by Generex. NGIO has the coronavirus vaccine to develop and a vaccine it is currently studying for breast cancer. Prostate research is underway as well. Other research is pending the new funding. Regarding number 4, I should have mentioned Merck. No doubt you all know about Keytruda being huge in cancer. The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda.
5) One of Generex's subs has a number of test kits for various ailments is working on a coronavirus test kit NOW.
6) Another sub, Olaregen has a wound care product being sold in the VA system and producing significant NEW revenue for Generex as of the last 3 months.
7) It was just announced two of the other subs have had a 400% increse in sales of their medical products recently
Over the next few day I will tell you about the MSO, HMO,Type 2 diabetes treatment and more.
Count yourselves lucky to be here now just before the good stuff is going to come together. Flippers will look back and regret having sold quite soon.
Did I mention Generex has already filed for UPLISTING ON THE NAZDAQ for GNBT? Waiting on the S-1 to be approved and the financing to be put to work.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...
Continue Reading
Navigating the Address Change Labyrinth Every time that welcome mat rolls out in a new spot, you're signing up for a mountain of paperwork. Sloth Move just painted a picture of the administrative mess awaiting those 1.8 million English households that decided 'new view, new digs' last year. Their analysis highlights why moving home means more than packing boxes—it's...
Continue Reading
Newmark Banks on Steamboat's Future Diving headfirst into the deep end, Newmark (NASDAQ: NMRK) just roped in a colossal $482.5 million loan for a new gem in Steamboat Springs, Colorado. Inking a deal of this magnitude ain't your everyday rinse-and-repeat; it's a bold move that speaks volumes about where the big shots think value's heading. The Financial Fuel: GoldenTree...
Continue Reading
A Celebration of Fans and Momentum Some things are bigger than just a match. The Kansas City Current’s event, 'One Current 2026: Bigger Home. Bigger Future.' ain't just another day on the pitch. This is about expanding a vision that has the whole town buzzing. On Sunday, October 25, the buzzhits fever pitch as CPKC Stadium rolls out the biggest event in its...
Continue Reading
When the Driver Disappears: Steps Forward Hit and run accidents can leave you feeling abandoned and unsure of what to do. In St. Tammany Parish, this scenario is all too familiar. Personal Injury Attorney Ross F. Lagarde cuts through the chaos, offering a clear path for those caught in this nightmare, explained in HelloNation's comprehensive guide. Prioritize Safety and...
Continue Reading
What's the 2025 Survey Telling Us? Numbers hit like a gut punch, don't they? The 2025 National Youth Risk Behavior Survey unveils some hard truths — truths that can't be softer just because we've made headway. We're talking about one in three high schoolers in this country feeling persistently down. That's about 33.3% of them, wrestling with sadness and hopelessness...
Continue Reading
AdminaHealth Unveils AI Data Assistant for Enterprises Amid the hustle and bustle of business operations, AdminaHealth has tossed a digital lifeline into the sea of billing chaos. Enter their AI-powered data assistant, now available to the big players on the Enterprise Tier within the AdminaHealth Billing Suite. This tool isn't just some gizmo for show; it's a genuine...
Continue Reading
Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...
Continue Reading
In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...
Continue Reading
Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...
Continue Reading
Top 5 Most Recently Viewed Articles
eBay Inc. Reports Second Quarter Results eBay Inc. (NASDAQ: EBAY), a leader in global commerce, has shared its latest financial figures, marking a notable quarter for the company. During this second quarter of 2025, eBay reported impressive metrics that reflect both resilience and strategic prowess in the market. Financial Performance Highlights For the quarter, eBay...
Continue Reading
AirConsole Expands Gaming with Trivia Crack for Volkswagen Today, AirConsole, an innovative in-car gaming platform, proudly announces the official launch of its gaming services on select Volkswagen models. This new integration brings a significant enhancement in the realm of in-car entertainment, making AirConsole accessible in several Volkswagen vehicles. This exciting...
Continue Reading
Cushman & Wakefield Achieves Perfection in LGBTQ+ Workplace Equality CHICAGO--Cushman & Wakefield (NYSE: CWK), an influential global real estate services firm, proudly announces its continued accomplishment of a perfect score of 100 on the Human Rights Campaign Foundation's Corporate Equality Index for 2025. This accolade recognizes the firm as a leader in promoting...
Continue Reading
Shelle Hobbs Celebrated as London Market Professional Of The Year TransEleven Claims Managers is excited to share that Chief Executive Officer Shelle Hobbs has earned the esteemed London Market Professional Of The Year Award, a recognition bestowed at the Women in Insurance Awards. This prestigious event took place at a well-known venue in London. Hobbs was recognized by...
Continue Reading
Verona Pharma Reaches Record Stock Price In a remarkable display of market confidence, Verona Pharma (NASDAQ: VRNA) has seen its stock soar to an all-time high of $43.76. This significant milestone not only reflects the company's resilient market performance but also emphasizes the strong growth trajectory that Verona Pharma has maintained over recent months. A Milestone...
Continue Reading